Idiopathic Pulmonary Fibrosis

In a phase 2 trial, pamrevlumab, a fully recombinant human monoclonal antibody against connective tissue growth factor, appeared to reduce the decline in lung function among patients with idiopathic pulmonary fibrosis.

When compared with placebo, nintedanib slowed the annual rate of decline in FVC in patients with progressive fibrosing interstitial lung disease other than idiopathic pulmonary fibrosis, researchers reported at the European Respiratory Society International Congress.

New data from a single-center study indicate that not only was the rate of mortality high among patients with advanced pulmonary sarcoidosis who were awaiting lung transplant, but the lung allocation score did not predict death on the waitlist in this patient population.

Among patients with idiopathic interstitial pneumonia associated with pulmonary hypertension, treatment with riociguat was linked to an increase in adverse events with no significant evidence of benefit, according to the RISE-IIP trial.

September has been designated Pulmonary Fibrosis Awareness Month — a time during which researchers and clinicians aim to improve the public’s knowledge about the disease. This September, efforts include several events and social media campaigns to support awareness of the disease, according to a press release from the Pulmonary Fibrosis Foundation.

Non-small cell lung cancer is associated with poorer prognosis and has a unique presentation in elderly patients with idiopathic pulmonary fibrosis, a recently published study showed

Among patients with idiopathic pulmonary fibrosis, the effects of nintedanib plus sildenafil, as compared with nintedanib alone, on quality of life and FVC did not differ significantly between patients with and those without evidence of right heart dysfunction, according to subgroup analyses of the INSTAGE trial.